Plasma cell leukemia is a rare disease associated with very poor survival with standard treatment. We report a patient affected by plasma cell leukemia treated with aggressive chemotherapy and autologous CD34-selected PBPC who achieved a complete remission now lasting more than 2 years. Molecular studies confirmed the presence of minimal residual disease (MRD) despite the absence of disease activity. High-dose chemotherapy with stem cell rescue may be applied to selected patients considering the impact of the treatment on survival. The meaning of molecular MRD in this setting is unclear. Keywords: plasma cell leukemia; autologous stem cell transplantation; minimal residual disease Plasma cell leukemia (PCL) is a rare form of malignant plasma cell disease accounting for 1-4% of myelomas. PCL is predominantly a disease of late adulthood and its course is highly unfavorable with an estimated 5 year relative survival rate of 13%. Current therapy of PCL is disappointing and is based on the standard combination of melphalan and prednisone although more intensive therapeutic programmes including cyclophosphamide-etoposide or vincristine, adriamycin and dexamethasone (VAD) are giving promising results. We describe a patient with de novo PCL treated with intensive chemotherapy and autologous CD34-selected peripheral blood progenitor cell tranplantation who achieved complete and sustained remission with a followup of 24 months. The course of PCL can be modified by the use of high-dose chemotherapy and autologous stem cell transplantation in selected patients.
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Case report
In October 1995, a 58-year-old female, otherwise asymptomatic, came to our attention because a routine serum protein electrophoresis disclosed the presence of paraproteins subsequently confirmed to be monoclonal IgG type at immunofixation. At admission the physical examination was unremarkable. Hemoglobin was 8.0 g/dl, platelet count 146 × 10 9 /l, WBC 8.3 × 10 9 /l. On differential count, peripheral blood neutrophils were 20%, lymphocytes 35%, monocytes 10% and immature plasma cells 35%. Immunophenotype was available only on the peripheral blood: CD3 62%, CD3/DR 17%; CD4 33%; CD8 39%; CD19 5%; CD57 25%; CD16 13%. Bone marrow aspiration revealed a massive plasma cell infiltration (65% immature plasma cells). Serum IgG was 5.9 g/l and free chains were detected in the urine. Serum LDH was 556 IU/l, total proteins were 11.4 g/dl, creatinine was 1.1 mg/dl, ␤2 microglobulin was not available at diagnosis. Skeletal bone survey did not detect lytic lesions.
Cytogenetic analysis on bone marrow mononuclear cells disclosed the following karyotype: 17 normal mitoses (46 XX), five pseudodiploid mitoses characterized by the presence of complex rearrangement: isochromosome (21q), 3q+, der(13).
Three courses of vincristine 0.4 mg, doxorubicin 9 mg/m 2 and prednisone 40 mg from days 1 to 4 (VAD) were planned. Laboratory evaluations before the third course showed the persistence of peripheral plasmacytosis with massive bone marrow infiltration. The patient was then switched to intermediate-dose cyclophosphamide and a complete remission was obtained at the end of two courses. High-dose cyclophosphamide (7 g/m 2 ) plus G-CSF 5 g/kg was then administered. Peripheral blood stem cells were harvested and the product of two consecutive leukaphereses was submitted to positive immunoselection with Ceprate SC (Cellpro, Bothell, WA, USA). A total of 10 × 10 6 /kg CD34 + cells was reinfused after conditioning with busulfan 4 mg/kg p.o. in divided doses for 4 consecutive days and melphalan 90 mg/m 2 day 5. Hemopoietic recovery after CD34-selected PBPCT was complete, PMN Ͼ0.5 × 10 9 /l were obtained at day +12 and a platelet count Ͼ50 × 10 9 /l was obtained at day +40.
Immune reconstitution was characterized by a slow recovery of the CD4 + lymphocyte subset with a persistent reduction of CD4/CD8 (0.5 at 1 and 2 years of followup) and by the presence of activated T cells coexpressing CD3/DR for at least 2 years after PBPCT. Maintenance therapy with ␣-interferon (3 × 10 6 IU s.c. on alternate days) was started 2 months after PBPCT. The patient is alive and in complete hematological and cytogenetic remission 24 months after PBPCT still on maintenance therapy with ␣-interferon.
Molecular studies
The evaluation of minimal residual disease (MRD) was performed through the molecular rearrangement of the heavy chain of the immunoglobulin by PCR technique using the primers FR3A (ACACGGCC/TC/GTGTATTACTGT) and JH (GACCCCGGTTCCTAGGGACCAGTGGC). 1 Genomic DNA from about 3 × 10 6 cells for each sample was extracted according to standard protocols. 2 The 100 l PCR reactions were performed as follow: 1 g genomic DNA, 30 pmol of each primer, 2.5 U of Taq polymerase (Amplitaq; Perkin Elmer-Cetus, Norwalk, CT, USA), 200 mol/l of each dNTP, 5 to 10 Ci of 32 P-deoxycytidine triphosphate ( 32 P-dCTP; ICN Pharmaceuticals, The Netherlands), 20 mmol/l Tris-HCl (pH 8.3), 50 mmol/l KCl and 1.5 mmol/l MgCl 2 . After a denaturation step (7 min at 94°C) amplification was performed by 30 cycles at 94°C for 1 min, at 56°C for 1 min, at 72°C for 1.5 min, with a final single extension step at 72°C for 7 min. All PCR reactions were carried out using DNA Thermal Cycler 480 (Perkin Elmer-Cetus). Four microliters of PCR product were separated on 6% polyacrylamide gel that was dried and exposed to X-ray film at room temperature for 12 h. The film was analyzed by scanner (Hewlett-Packard, Geneva, Switzerland). The leukapheretic products showed a persistent positivity of the monoclonal band. Purified CD34 + cell fraction showed a positivity for the original rearrangement but to a lesser extent. At follow-up at 1 and 2 years, the monoclonal band still persists despite clinical and laboratory remission (Figure 1 ).
Discussion
Plasma cell leukemia (PCL) is a rare disease occurring in 2-4% of newly diagnosed patients and it is characterized by a malignant proliferation of plasma cells massively involving the peripheral blood, accounting for more than 
CD34 + selected fraction; (4) bone marrow day +30; (5) bone marrow day +60; (6) bone marrow month +12; (7) bone marrow month +24.
20% of the differential white blood cell (WBC) or as an absolute number greater than 2 × 10 9 /l.
3,4 PCL arises as a late manifestation in patients with multiple myeloma or it can occur de novo (primary PCL). Cytogenetic findings in PCL are most often characterized by complex karyotypes, with nonrandom abnormalities primarily involving chromosomes 1, 7, 8, 11, 14 and 13. 5 The outcome for patients with PCL is disappointing with a 5 year relative survival rate of 13% in a recent report by Hernandez and co-workers. 6 These results are primarily obtained with standard treatment including a combination of one or more alkylating agents with prednisone. Encouraging data have been obtained by the use of more intensive chemotherapeutic regimen (VAD or high-dose cyclophosphamide or VP-16). These regimens, although more toxic, were able to induce complete remission and improve overall survival in selected patients. 4 Moreover, the use of myeloablative therapy with stem cell support has been recently introduced in the management of PCL responsive to chemotherapy and preliminary results are encouraging. [2] [3] [4] [5] [6] [7] [8] [9] Our patient was unresponsive to VAD but achieved a complete response after cyclophosphamide. After mobilization with high-dose cyclophosphamide + G-CSF a large number of PBPC was collected and CD34
+ cell selection was carried out. Hemopoietic recovery after PBPCT was prompt and complete. Immune reconstitution was characterized by a slow recovery of CD4 + lymphocytes and by the appearance of activated T cells persisting for at least 2 years after PBPCT.
At follow-up the patient is in complete remission at 2 years. Despite the absence of hematological, laboratory and clinical findings of the original disease, minimal residual disease is still detectable at the molecular level. Currently, the significance of disease persistence at the molecular level in the purged graft and during follow-up is unknown and adequate follow-up of patients is required to validate its role, if any, in the management of myeloma patients submitted to high-dose chemotherapy and stem cell transplantation. PCL, although a rare disease, should be treated with intensive chemotherapy and autologous stem cell transplantation at least in selected patients, considering the major impact of a correct strategy on survival. The role of purging in multiple myeloma and PCL is debatable 10 and recent results showed no difference in a large series of myeloma patients receiving immunoselected CD34 + or unfractionated PBPC. 11 These observations deserve serious consideration for economical, practical and ethical reasons in the design of new protocols.
